Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
Background The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil. However, patients with renal or cardiac dysfunction and elderly patients are ineligible for a CDDP-containing regimen because of toxicities. Oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) therapy has less renal toxicity than CDDP-containing regimens and does not require hydration. However, there are limited data on preoperative FOLFOX therapy in these patients. Methods This retrospective study analyzed patients with resectable LAESCC who were aged ≥ 75 years or had renal or cardiac dysfunction and received preoperative FOLFOX between 2019 and 2021. FOLFOX was administered every 2 weeks for 3 or 4 cycles and was followed by surgery. Adverse events associated with chemotherapy, the complete resection (R0) rate, relative dose intensity (RDI), and histopathological response were evaluated. Results Thirty-five patients were eligible. Median age was 77 (range 65–89) years; 68.6% were aged ≥ 75 years, 74.3% had renal dysfunction, and 17.1% had cardiac dysfunction. The RDI was 70.2% and 87.1% for bolus and continuous intravenous 5-fluorouracil, respectively and 85.2% for oxaliplatin. The most common grade ≥ 3 adverse events were neutropenia (60.0%) and leucopenia (28.6%). Two patients (5.7%) had febrile neutropenia and grade 3 pneumonia. Thirty-one patients underwent surgery. The R0 resection rate was 87.1%, and there was no histopathological evidence of residual tumor in 16.1%. There were no treatment-related deaths. Conclusions Preoperative FOLFOX had a manageable safety profile and showed favorable short-term efficacy in patients with resectable LAESCC who were ineligible for CDDP-containing treatment..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Esophagus - 20(2022), 1 vom: 01. Sept., Seite 109-115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kadono, Toru [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
5-Fluorouracil |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10388-022-00951-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2080225766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2080225766 | ||
| 003 | DE-627 | ||
| 005 | 20230515070239.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10388-022-00951-4 |2 doi | |
| 035 | |a (DE-627)OLC2080225766 | ||
| 035 | |a (DE-He213)s10388-022-00951-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kadono, Toru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil. However, patients with renal or cardiac dysfunction and elderly patients are ineligible for a CDDP-containing regimen because of toxicities. Oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) therapy has less renal toxicity than CDDP-containing regimens and does not require hydration. However, there are limited data on preoperative FOLFOX therapy in these patients. Methods This retrospective study analyzed patients with resectable LAESCC who were aged ≥ 75 years or had renal or cardiac dysfunction and received preoperative FOLFOX between 2019 and 2021. FOLFOX was administered every 2 weeks for 3 or 4 cycles and was followed by surgery. Adverse events associated with chemotherapy, the complete resection (R0) rate, relative dose intensity (RDI), and histopathological response were evaluated. Results Thirty-five patients were eligible. Median age was 77 (range 65–89) years; 68.6% were aged ≥ 75 years, 74.3% had renal dysfunction, and 17.1% had cardiac dysfunction. The RDI was 70.2% and 87.1% for bolus and continuous intravenous 5-fluorouracil, respectively and 85.2% for oxaliplatin. The most common grade ≥ 3 adverse events were neutropenia (60.0%) and leucopenia (28.6%). Two patients (5.7%) had febrile neutropenia and grade 3 pneumonia. Thirty-one patients underwent surgery. The R0 resection rate was 87.1%, and there was no histopathological evidence of residual tumor in 16.1%. There were no treatment-related deaths. Conclusions Preoperative FOLFOX had a manageable safety profile and showed favorable short-term efficacy in patients with resectable LAESCC who were ineligible for CDDP-containing treatment. | ||
| 650 | 4 | |a Esophageal neoplasms | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Oxaliplatin | |
| 650 | 4 | |a 5-Fluorouracil | |
| 650 | 4 | |a Leucovorin | |
| 700 | 1 | |a Yamamoto, Shun |4 aut | |
| 700 | 1 | |a Hirose, Toshiharu |4 aut | |
| 700 | 1 | |a Ikeda, Go |4 aut | |
| 700 | 1 | |a Ohara, Akihiro |4 aut | |
| 700 | 1 | |a Itoyama, Mai |4 aut | |
| 700 | 1 | |a Yokoyama, Kazuki |4 aut | |
| 700 | 1 | |a Honma, Yoshitaka |4 aut | |
| 700 | 1 | |a Hashimoto, Taiki |4 aut | |
| 700 | 1 | |a Sekine, Shigeki |4 aut | |
| 700 | 1 | |a Ishiyama, Koshiro |4 aut | |
| 700 | 1 | |a Oguma, Junya |4 aut | |
| 700 | 1 | |a Daiko, Hiroyuki |4 aut | |
| 700 | 1 | |a Kato, Ken |0 (orcid)0000-0002-1733-5072 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Esophagus |d Springer Nature Singapore, 2003 |g 20(2022), 1 vom: 01. Sept., Seite 109-115 |w (DE-627)527581321 |w (DE-600)2277692-8 |x 1612-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:1 |g day:01 |g month:09 |g pages:109-115 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10388-022-00951-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 1 |b 01 |c 09 |h 109-115 | ||